Information  X 
Enter a valid email address

Circassia Pharms PLC Ord 0.08P (CIR)

Related News

15-Oct-2019 08:50 AM

Broker Forecast - Peel Hunt issues a broker note on Circassia Pharmaceuticals Plc

Peel Hunt today reaffirms its buy investment rating on Circassia Pharmaceuticals Plc (LON:CIR) and cut its price target to 70p (from 90p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
26-Sep-2019 09:13 AM

Losses widen at Circassia Pharmaceuticals; reduction in cash outflow since post period end

Losses grew to £29.0m from £23.5 with revenue advancing 40% to £27.9m as announced in Circassia Pharmaceuticals interim report for the period ending 30 June 2019. The company said growth drivers were in place to achieve £60-&poun
26-Sep-2019 09:00 AM

Broker Forecast - finnCap issues a broker note on Circassia Pharmaceuticals Plc

finnCap today initiates coverage of Circassia Pharmaceuticals Plc (LON:CIR) with a corporate investment rating and price target of 80p. Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
12-Aug-2019 07:29 AM

Circassia Pharmaceuticals appoints Jonathan Emms as chief operating officer

Circassia Pharmaceuticals appointed Jonathan Emms to the newly-created role of chief operating officer. As COO, Emms would further strengthen Circassia's commercial focus and lead the company's global commercial strategy and operational manag
12-Mar-2019 08:50 AM

Broker Forecast - Peel Hunt issues a broker note on Circassia Pharmaceuticals Plc

Peel Hunt today reaffirms its buy investment rating on Circassia Pharmaceuticals Plc (LON:CIR) and set its price target at 90p. Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
24-Jan-2019 02:20 PM

Broker Forecast - RBC Capital Markets issues a broker note on Circassia Pharmaceuticals Plc

RBC Capital Markets today reaffirms its sector performer investment rating on Circassia Pharmaceuticals Plc (LON:CIR) and cut its price target to 65p (from 81p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.
17-Oct-2018 04:00 PM

Broker Forecast - RBC Capital Markets issues a broker note on Circassia Pharmaceuticals Plc

RBC Capital Markets today reaffirms its sector performer investment rating on Circassia Pharmaceuticals Plc (LON:CIR) and cut its price target to 81p (from 86p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.
27-Sep-2018 08:00 AM

Broker Forecast - Peel Hunt issues a broker note on Circassia Pharmaceuticals Plc

Peel Hunt today upgrades its investment rating on Circassia Pharmaceuticals Plc (LON:CIR) to buy (from hold). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
16-May-2018 08:10 AM

Broker Forecast - Peel Hunt issues a broker note on Circassia Pharmaceuticals Plc

Peel Hunt today reaffirms its hold investment rating on Circassia Pharmaceuticals Plc (LON:CIR) and cut its price target to 120p (from 130p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
15-May-2018 10:40 AM

Broker Forecast - JP Morgan Cazenove issues a broker note on Circassia Pharmaceuticals Plc

JP Morgan Cazenove today reaffirms its neutral investment rating on Circassia Pharmaceuticals Plc (LON:CIR) and cut its price target to 100p (from 125p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
24-Apr-2018 12:10 PM

Broker Forecast - Numis issues a broker note on Circassia Pharmaceuticals Plc

Numis today reaffirms its buy investment rating on Circassia Pharmaceuticals Plc (LON:CIR) and cut its price target to 140p (from 180p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
24-Apr-2018 09:50 AM

Broker Forecast - Peel Hunt issues a broker note on Circassia Pharmaceuticals Plc

Peel Hunt today reaffirms its hold investment rating on Circassia Pharmaceuticals Plc (LON:CIR) and set its price target at 130p. Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
08-Feb-2018 08:41 AM

Circassia receives contract from Vizient for asthma management products

Circassia Pharmaceuticals plc announced Thursday that it received a multi-year contract for its Niox Vero asthma management products from Vizient. The contract is expected to provide Circassia with a simplified route to access Vizient members as potentia
04-Dec-2017 07:17 AM

Circassia's Tudorza meets primary endpoints in study

Circassia Pharmaceuticals has announced positive top-line results from the ASCENT phase IV post-marketing study of Tudorza in over 3,600 patients with moderate to very severe chronic obstructive pulmonary disease (COPD) and documented cardiovascular risk
29-Nov-2017 07:53 AM

Circassia welcomes new NICE asthma guidelines

Circassia Pharmaceuticals has welcomed the publication of new clinical guidelines by the UK's National Institute for Health and Care Excellence (NICE), which recommend the use of fractional exhaled nitric oxide (FeNO) testing as part of asthma diagno
28-Sep-2017 10:30 AM

Broker Forecast - JP Morgan Cazenove issues a broker note on Circassia Pharmaceuticals Plc

JP Morgan Cazenove today reaffirms its neutral investment rating on Circassia Pharmaceuticals Plc (LON:CIR) and cut its price target to 110p (from 120p). Story provided by StockMarketWire.com...
12-Sep-2017 08:01 AM

Circassia launches nasal application in Europe

Circassia Pharmaceuticals, a speciality pharmaceutical company focused on respiratory disease, has announced the European launch of the NIOX VERO nasal application for the screening of primary ciliary dyskinesia (PCD). Circassia launched the applicatio
07-Sep-2017 10:10 AM

Broker Forecast - Numis issues a broker note on Circassia Pharmaceuticals Plc

Numis today reaffirms its buy investment rating on Circassia Pharmaceuticals Plc (LON:CIR) and set its price target at 180p. Story provided by StockMarketWire.com...
26-Apr-2017 02:10 PM

Broker Forecast - Peel Hunt issues a broker note on Circassia Pharmaceuticals Plc

Peel Hunt today downgrades its investment rating on Circassia Pharmaceuticals Plc (LON:CIR) to hold (from add) and cut its price target to 130p (from 150p). Story provided by StockMarketWire.com...
25-Apr-2017 09:48 AM

Circassia losses widen

Circassia Pharmaceuticals' underlying losses rose to £57.4m in the year ended 31 December - up from £50.0m in 2015 - and total losses increased to £137.4m from £50.0m last time. Revenues increased to £23.1m (2015: &p
18-Apr-2017 07:23 AM

Circassia disappointed by house mite dust allergy results

Top-line results from Circassia Pharmaceuticals' investigational house dust mite allergy immunotherapy phase IIb field study failed to achieve to its primary endpoint. Circassia said that in the study, both the active treatment and placebo greatly
12-Apr-2017 09:48 AM

Circassia schedules FY results

Circassia Pharmaceuticals will announce its preliminary results for the year ended 31 December on 25 April. At 9:48am: (LON:CIR) Circassia Pharmaceuticals Plc share price was +3.88p at 102.13p Story provided by StockMarketWire.com...
04-Apr-2017 03:30 PM

Broker Forecast - Numis issues a broker note on Circassia Pharmaceuticals Plc

Numis today reaffirms its buy investment rating on Circassia Pharmaceuticals Plc (LON:CIR) and set its price target at 174p. Story provided by StockMarketWire.com...
20-Mar-2017 11:30 AM

Broker Forecast - Stifel issues a broker note on Circassia Pharmaceuticals Plc

Stifel today upgrades its investment rating on Circassia Pharmaceuticals Plc (LON:CIR) to buy (from hold) and raised its price target to 150p (from 99p). Story provided by StockMarketWire.com...
17-Mar-2017 07:30 AM

Circassia collaboration with AstraZeneca

Circassia Pharmaceuticals has reached agreement with AstraZeneca to enter into a collaboration and secure certain US commercial rights to two chronic obstructive pulmonary disease products, Tudorza and Duaklir, for a maximum total consideration of US$230m
 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t